Effect of Preexisting Cardiometabolic Disease in Patients Using Assisted Reproductive Technology: A Comparative Study [ID 536]

INTRODUCTION: Few studies have examined the effect of cardiovascular and metabolic disease, or cardiometabolic disease (CMD), on assisted reproductive technology (ART) outcomes. This study compares outcomes between ART patients with and without CMD. METHODS: This is an IRB-approved retrospective cohort study with patients undergoing ART at a large academic center from 2020 to 2023. We included those undergoing fresh or frozen embryo transfer through our clinic’s database, The Society for ART Clinic Outcome Reporting System, and excluded gestational carrier cycles. Analyses utilized t-test and chi-squared (or Fisher’s exact) to compare continuous and categorical variables, respectively, with a value of P ≤.05. Primary outcome was live birth rate (LBR); secondary outcomes were clinical pregnancy rate, delivery route, and fetal weight. RESULTS: We identified 1,981 patients who underwent embryo transfer cycles between 2020 and 2023. Patients with CMD (N=347) were more likely to be older (36.1 versus 35.2 years, P <.01), to be smokers (14.4% versus 7.9%, P <.01), and have higher body mass index (28.2 kg/m 2 versus 26.3 kg/m 2 , P <.01). We found no difference in anti-müllerian hormone levels. Cardiometabolic disease patients were more likely to have tubal disorder (10.1% versus 6.3%, P =.01), polycystic ovary syndrome (16.4% versus 7.2%, P <.01), or ovulation disorder (27.1% versus 21.7%, P =.03). They also had a higher number of autologous oocytes retrieved (18.8 versus 17.4, P <.03). We found no difference in LBR or secondary outcomes. CONCLUSIONS/IMPLICATIONS: No association was found between preexisting CMD and LBR after embryo transfer. Further research is needed to characterize the effect of CMD on other ART-related outcomes, such as adverse events and maternal/neonatal outcomes.